(Q37427903)

English

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group

scientific article published on 05 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myeloid leukemia

1 reference

based on heuristic

inferred from title

myeloid leukemia associated with Down Syndrome

1 reference

based on heuristic

inferred from title

author name string

April D Sorrell

1

1 reference

Europe PubMed Central

20 August 2017

Todd A Alonzo

2

1 reference

Europe PubMed Central

20 August 2017

Joanne M Hilden

3

1 reference

Europe PubMed Central

20 August 2017

Robert B Gerbing

4

1 reference

Europe PubMed Central

20 August 2017

Thomas W Loew

5

1 reference

Europe PubMed Central

20 August 2017

Lois Hathaway

6

1 reference

Europe PubMed Central

20 August 2017

Dorothy Barnard

7

1 reference

Europe PubMed Central

20 August 2017

Jeffrey W Taub

8

1 reference

Europe PubMed Central

20 August 2017

Yaddanapudi Ravindranath

9

1 reference

Europe PubMed Central

20 August 2017

Franklin O Smith

10

1 reference

Europe PubMed Central

20 August 2017

Robert J Arceci

11

1 reference

Europe PubMed Central

20 August 2017

William G Woods

12

1 reference

Europe PubMed Central

20 August 2017

Alan S Gamis

13

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

5 March 2012

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

118

1 reference

Europe PubMed Central

20 August 2017

19

1 reference

Europe PubMed Central

20 August 2017

4806-4814

1 reference

Europe PubMed Central

20 August 2017

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

23 August 2017

Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

14 September 2017

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

14 September 2017

Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

26 June 2018

Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

2 September 2018

Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

2 September 2018

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

2 September 2018

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879144

2 September 2018

Definition of a standard-risk group in children with AML

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27484

21 January 2018

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27484

21 January 2018

Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27484

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37427903&oldid=1532438446"